Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Lies Beyond Health Reform: Pfizer's Kindler Talks Innovation, Jobs

Executive Summary

PhRMA's incoming chairman, Pfizer CEO Jeff Kindler, is pushing redoubled efforts toward a public/private solution on advancing innovation within the U.S. biopharmaceutical industry

You may also be interested in...



Final Health Reform Bill Looks Positive For Pharma Firms

It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result

Final Health Reform Bill Looks Positive For Pharma Firms

It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result

Enrolling 31 Mil.: Families USA Pushing Cooperative Plan To Pharma, Others

Consumer health care advocacy group Families USA is working to catalyze formation of a health care stakeholder cooperative, including pharmaceutical firms, insurers and hospitals, to help 31 million uninsured individuals obtain the coverage that would be provided under health reform legislation pending in Congress - assuming the legislation passes

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel